Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1C | P00326 | 1/20 | 0.47 |
| ▸ | ADH1A | P07327 | 1/20 | 0.47 |
| ▸ | ADH4 | P08319 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | LSS | P48449 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11569526 | 0.92 | ADH1C (0.53) | ADH1CADH1AADH4DNM1GBA1 | |
| SCHEMBL1678954 | 0.92 | ADH1C (0.53) | ADH1CADH1AADH4DNM1GBA1 | |
| SCHEMBL11570725 | 0.92 | ADH1C (0.53) | ADH1CADH1AADH4DNM1GBA1 | |
| SCHEMBL23767402 | 0.89 | ADH1C (0.50) | ADH1CADH1AADH4DNM1GBA1 | |
| SCHEMBL1680185 | 0.89 | ADH1C (0.50) | ADH1CADH1AADH4DNM1GBA1 | |
| SCHEMBL17351084 | 0.85 | DNM1 (0.48) | ADH1CADH1AADH4DNM1GBA1 | |
| SCHEMBL27445925 | 0.83 | ADH1C (0.50) | ADH1CADH1AADH4DNM1GBA1 | |
| SCHEMBL17351009 | 0.83 | DNM1 (0.46) | ADH1CADH1AADH4DNM1GBA1 | |
| SCHEMBL24437737 | 0.83 | DNM1 (0.44) | ADH1CADH1AADH4DNM1GBA1 | |
| SCHEMBL1678797 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | MTREX, HAVCR2, TSG101 | ADH1C 3663/4885ADH1A 3247/4885ADH4 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.